

HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM KERENDIA® FOR HEALTHY U

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 855-856-5694

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Kerendia® (finerenone)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Does the member have a confirmed diagnosis of chronic kidney disease with moderate (30-300mg/g) albuminuria and a history of diabetic retinopathy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does the member have a confirmed diagnosis of chronic kidney disease with severe (300-5000mg/g) albuminuria?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does the member have a confirmed diagnosis of Type 2 Diabetes Mellitus?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does documentation show that the member has tried and failed, or has a contraindication/intolerance to, both of the following: <ul style="list-style-type: none"> • Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) at maximally tolerated FDA-labeled dose • Farxiga® (dapagliflozin) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Do recent laboratory results show serum potassium level less than 4.8mEq/L prior to Kerendia® initiation?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member show a continued need for therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does documentation show the therapy is effective and tolerable?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

4. Has continued monitoring of potassium levels been performed?	<input type="checkbox"/>	<input type="checkbox"/>	
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM-HU-124
 Origination Date: 08/23/2021
 Reviewed/Revised Date: 08/24/2022
 Next Review Date: 08/24/2023
 Current Effective Date: 09/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.